A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma. Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results